Frontiers in Immunology (Nov 2024)

Mevalonate kinase deficiency: an updated clinical overview and revision of the SHARE recommendations

  • Lilla Lengvári,
  • Kata Takács,
  • Anna Lengyel,
  • Annamária Pálinkás,
  • Carine Helena Wouters,
  • Isabelle Koné-Paut,
  • Jasmin Kuemmerle-Deschner,
  • Jerold Jeyaratnam,
  • Jordi Anton,
  • Helen Jane Lachmann,
  • Marco Gattorno,
  • Michael Hofer,
  • Nataša Toplak,
  • Peter Weiser,
  • Tilmann Kallinich,
  • Seza Ozen,
  • Véronique Hentgen,
  • Yosef Uziel,
  • Zsuzsanna Horváth,
  • Márton Szabados,
  • Paul Brogan,
  • Tamás Constantin,
  • Joost Frenkel

DOI
https://doi.org/10.3389/fimmu.2024.1466844
Journal volume & issue
Vol. 15

Abstract

Read online

Mevalonate kinase deficiency (MKD), a rare auto-inflammatory disorder, arises from mutations in the MVK gene, disrupting isoprenoid biosynthesis, and affecting cellular processes. This comprehensive review provides an updated perspective on MKD, including its aetiology, pathogenesis, diagnostic modalities, and therapeutic strategies. Based on recent research and clinical advances, our objective is to bridge the knowledge gaps in the 2015 SHARE guidelines. By describing molecular mechanisms, diagnostic dilemmas, and emerging therapies, this article should serve as a resource for clinicians and researchers, promoting a deeper understanding of MKD and guiding optimal patient care.

Keywords